AAAAAA

   
Results: 1-8 |
Results: 8
DEPLETION OF ANTI-GAL-ALPHA-1-3GAL ANTIBODY IN BABOONS BY SPECIFIC ALPHA-GAL IMMUNOAFFINITY COLUMNS
Authors: KOZLOWSKI T IERINO FL LAMBRIGTS D FOLEY A ANDREWS D AWWAD M MONROY R COSIMI AB COOPER DKC SACHS DH
Citation: T. Kozlowski et al., DEPLETION OF ANTI-GAL-ALPHA-1-3GAL ANTIBODY IN BABOONS BY SPECIFIC ALPHA-GAL IMMUNOAFFINITY COLUMNS, Xenotransplantation, 5(2), 1998, pp. 122-131
DEPLETION OF ANTI-GAL-ALPHA-1-3GAL ANTIBODY IN BABOONS BY SPECIFIC ALPHA-GAL IMMUNOAFFINITY COLUMNS
Authors: KOZLOWSKI T IERINO FL LAMBRIGTS D FOLEY A ANDREWS D AWWAD M MONROY R COSIMI AB COOPER DKC SACHS DH
Citation: T. Kozlowski et al., DEPLETION OF ANTI-GAL-ALPHA-1-3GAL ANTIBODY IN BABOONS BY SPECIFIC ALPHA-GAL IMMUNOAFFINITY COLUMNS, Xenotransplantation, 5(2), 1998, pp. 122-131
ANTI-GAL-ALPHA-1-3GAL ANTIBODY-RESPONSE TO PORCINE BONE-MARROW IN UNMODIFIED BABOONS AND BABOONS CONDITIONED FOR TOLERANCE INDUCTION
Authors: KOZLOWSKI T MONROY R XU YX GLASER R AWWAD M COOPER DKC SACHS DH
Citation: T. Kozlowski et al., ANTI-GAL-ALPHA-1-3GAL ANTIBODY-RESPONSE TO PORCINE BONE-MARROW IN UNMODIFIED BABOONS AND BABOONS CONDITIONED FOR TOLERANCE INDUCTION, Transplantation, 66(2), 1998, pp. 176-182
REMOVAL OF ANTIPORCINE NATURAL ANTIBODIES FROM HUMAN AND NONHUMAN PRIMATE PLASMA IN-VITRO AND IN-VIVO BY A GAL-ALPHA-1-3GAL-BETA-1-4-BETA-GLC-X IMMUNOAFFINITY COLUMN
Authors: XU Y LORF T SABLINSKI T GIANELLO P BAILIN M MONROY R KOZLOWSKI T AWWAD M COOPER DKC SACHS DH
Citation: Y. Xu et al., REMOVAL OF ANTIPORCINE NATURAL ANTIBODIES FROM HUMAN AND NONHUMAN PRIMATE PLASMA IN-VITRO AND IN-VIVO BY A GAL-ALPHA-1-3GAL-BETA-1-4-BETA-GLC-X IMMUNOAFFINITY COLUMN, Transplantation, 65(2), 1998, pp. 172-179
A PHASE-II STUDY OF BTI-322, A MONOCLONAL ANTI-CD2 ANTIBODY, FOR TREATMENT OF STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE
Authors: PRZEPIORKA D PHILLIPS GL RATANATHARATHORN V COTTLERFOX M SEHN LH ANTIN JH LEBHERZ D AWWAD M HOPE J MCCLAIN JB
Citation: D. Przepiorka et al., A PHASE-II STUDY OF BTI-322, A MONOCLONAL ANTI-CD2 ANTIBODY, FOR TREATMENT OF STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE, Blood, 92(11), 1998, pp. 4066-4071
PREVENTION OF REJECTION WITH BTI-322 AFTER RENAL-TRANSPLANTATION (RESULTS AT 9 MONTHS)
Authors: BESSE T MALAISE J MOURAD M PIRSON Y HOPE J AWWAD M WHITESCHARF M SQUIFFLET JP
Citation: T. Besse et al., PREVENTION OF REJECTION WITH BTI-322 AFTER RENAL-TRANSPLANTATION (RESULTS AT 9 MONTHS), Transplantation proceedings, 29(5), 1997, pp. 2425-2426
APHERESIS AND COLUMN ABSORPTION FOR SPECIFIC REMOVAL OF GAL-ALPHA-1,3GAL NATURAL ANTIBODIES IN A PIG-TO-BABOON MODEL
Authors: KOZLOWSKI T FUCHIMOTO Y MONROY R BAILIN M MARTINEZRUIZ R FOLEY A XU Y AWWAD M FISHMAN J ANDREWS D RITZENTHALER J SABLINSKI T IERINO FL SACHS DH
Citation: T. Kozlowski et al., APHERESIS AND COLUMN ABSORPTION FOR SPECIFIC REMOVAL OF GAL-ALPHA-1,3GAL NATURAL ANTIBODIES IN A PIG-TO-BABOON MODEL, Transplantation proceedings, 29(1-2), 1997, pp. 961-961
MODIFICATION OF MONOCLONAL-ANTIBODY CARBOHYDRATES BY OXIDATION, CONJUGATION, OR DEOXYMANNOJIRIMYCIN DOES NOT INTERFERE WITH ANTIBODY EFFECTOR FUNCTIONS
Authors: AWWAD M STROME PG GILMAN SC AXELROD HR
Citation: M. Awwad et al., MODIFICATION OF MONOCLONAL-ANTIBODY CARBOHYDRATES BY OXIDATION, CONJUGATION, OR DEOXYMANNOJIRIMYCIN DOES NOT INTERFERE WITH ANTIBODY EFFECTOR FUNCTIONS, Cancer immunology and immunotherapy, 38(1), 1994, pp. 23-30
Risultati: 1-8 |